Anna Boltong1, Russell Keast, Sanchia Aranda. 1. Melbourne School of Health Sciences, The University of Melbourne, Melbourne, VIC, Australia. a.boltong@pgrad.unimelb.edu.au
Abstract
PURPOSE: Self-reported taste alterations are common in people receiving chemotherapy; however, it is usually unclear whether these reports refer to changes to the sense of taste itself or to problems related to the broader phenomenon of flavour, or the hedonic experience of eating and drinking. The purpose of this study was to explore patient and carer descriptions, experiences and consequences of taste and flavour changes associated with oxaliplatin treatment. METHODS: This study utilised a grounded theory research design. Purposeful sampling was used to recruit eligible patients who had self-reported taste changes in relation to oxaliplatin-containing chemotherapy for colorectal cancer. Content analysis of interview data was performed using an analysis framework derived from previous sensory and nutritional sciences and supportive care research. RESULTS: Ten patients and four carers participated in semi-structured interviews. The overarching theme identified from the data was reduced food enjoyment. In addition to changes to taste, participants described sensory and hedonic changes which influence overall flavour perception and food enjoyment. Reduced food enjoyment had dietary, social and emotional consequences for patients and carers. CONCLUSIONS: 'Taste' problems during oxaliplatin treatment mostly relate to the broader phenomena of flavour. This study has helped to unravel the major sensory determinants of the eating and drinking experience in the chemotherapy setting and has provided guidance regarding relevant and measurable endpoints of chemotherapy-related flavour changes. There remains a gap in knowledge between the pattern of flavour changes associated with chemotherapy treatment and how this influences dietary intake and nutritional status.
PURPOSE: Self-reported taste alterations are common in people receiving chemotherapy; however, it is usually unclear whether these reports refer to changes to the sense of taste itself or to problems related to the broader phenomenon of flavour, or the hedonic experience of eating and drinking. The purpose of this study was to explore patient and carer descriptions, experiences and consequences of taste and flavour changes associated with oxaliplatin treatment. METHODS: This study utilised a grounded theory research design. Purposeful sampling was used to recruit eligible patients who had self-reported taste changes in relation to oxaliplatin-containing chemotherapy for colorectal cancer. Content analysis of interview data was performed using an analysis framework derived from previous sensory and nutritional sciences and supportive care research. RESULTS: Ten patients and four carers participated in semi-structured interviews. The overarching theme identified from the data was reduced food enjoyment. In addition to changes to taste, participants described sensory and hedonic changes which influence overall flavour perception and food enjoyment. Reduced food enjoyment had dietary, social and emotional consequences for patients and carers. CONCLUSIONS: 'Taste' problems during oxaliplatin treatment mostly relate to the broader phenomena of flavour. This study has helped to unravel the major sensory determinants of the eating and drinking experience in the chemotherapy setting and has provided guidance regarding relevant and measurable endpoints of chemotherapy-related flavour changes. There remains a gap in knowledge between the pattern of flavour changes associated with chemotherapy treatment and how this influences dietary intake and nutritional status.
Authors: Allan J Hovan; P Michele Williams; Peter Stevenson-Moore; Yula B Wahlin; Kirsten E O Ohrn; Linda S Elting; Fred K L Spijkervet; Michael T Brennan Journal: Support Care Cancer Date: 2010-05-22 Impact factor: 3.603
Authors: C Hürny; J Bernhard; A S Coates; M Castiglione-Gertsch; H F Peterson; R D Gelber; J F Forbes; C M Rudenstam; E Simoncini; D Crivellari; A Goldhirsch; H J Senn Journal: Lancet Date: 1996-05-11 Impact factor: 79.321
Authors: R S Wickham; M Rehwaldt; C Kefer; S Shott; K Abbas; E Glynn-Tucker; C Potter; C Blendowski Journal: Oncol Nurs Forum Date: 1999-05 Impact factor: 2.172
Authors: Elfriede R Greimel; Vesna Bjelic-Radisic; Jacobus Pfisterer; Felix Hilpert; Fedor Daghofer; Andreas du Bois Journal: J Clin Oncol Date: 2006-02-01 Impact factor: 44.544
Authors: Joel B Epstein; Safira Marques de Andrade E Silva; Geena L Epstein; Jorge Henrique Santos Leal; Andrei Barasch; Gregory Smutzer Journal: Support Care Cancer Date: 2019-03-29 Impact factor: 3.603
Authors: Marcin Mardas; Małgorzata Jamka; Radosław Mądry; Jarosław Walkowiak; Marietta Krótkopad; Marta Stelmach-Mardas Journal: Support Care Cancer Date: 2014-10-02 Impact factor: 3.603
Authors: Robyn Loves; Deborah Tomlinson; Christina Baggott; David Dix; Paul Gibson; Shannon Hyslop; Donna L Johnston; Andrea D Orsey; Carol Portwine; Victoria Price; Tal Schechter; Magimairajan Vanan; Susan Kuczynski; Brenda Spiegler; George A Tomlinson; L Lee Dupuis; Lillian Sung Journal: Support Care Cancer Date: 2018-10-15 Impact factor: 3.603
Authors: Robyn Loves; Erin Plenert; Vivian Tomlinson; Sasha Palmert; Gloria Green; Tal Schechter; Deborah Tomlinson; Emily Vettese; Sue Zupanec; L Lee Dupuis; Lillian Sung Journal: Qual Life Res Date: 2019-07-01 Impact factor: 4.147
Authors: Yfke C de Vries; Esther Helmich; Matty D A Karsten; Sanne Boesveldt; Renate M Winkels; Hanneke W M van Laarhoven Journal: Support Care Cancer Date: 2016-02-27 Impact factor: 3.603
Authors: Anna Boltong; Sanchia Aranda; Russell Keast; Rochelle Wynne; Prudence A Francis; Jacqueline Chirgwin; Karla Gough Journal: PLoS One Date: 2014-07-31 Impact factor: 3.240